Stock listing

OTC:PHGUF Pharming Group NV Stock

US listing (OTC) of Pharming Group NV · home listing Euronext:PHARM

Follow Pharming Group NV into a list and get an email when it puts out news.

Share price · OTC:PHGUF

$0.955 USD 0.000 (0.0%)

Close on Oct 27, 2026

Day range
$0.955 – $0.955 USDOct 27, 2026
Market cap
$675.9M USDAt the close on Oct 27, 2026 · price × 707.8M shares outstanding
Pharming Group NV logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
Euronext:PHARM · Home€1.08 EUR+0.026 (+2.5%)24,112,331€1.072€1.108€1.046€1.054Close on Oct 27, 2026
NASDAQ:PHAR$11.87 USD+0.67 (+6.0%)19,184$12.01$12.19$11.76$11.20Close on Oct 27, 2026
OTC:PHGUF$0.955 USD0.000 (0.0%)—$0.955$0.955$0.955$0.955Close on Oct 27, 2026
Frankfurt:PHG€10.60 EUR+0.10 (+1.0%)—€10.10€10.60€10.10€10.50Close on Oct 27, 2026
Stuttgart:PHGN€1.077 EUR—1,197€1.041€1.096€1.041—Close on Oct 27, 2026
Ticker
OTC:PHGUF
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
OTC
Currency
USD

What changed lately

Calls

Replays

  • Pharming Group (Euronext:PHARM) Q2 2026 Earnings Call

    Thu, Jul 30, 2026 · 7:30 AM ET

    Watch Transcript

  • Pharming Group (Euronext:PHARM) Q1 2026 Earnings Call

    Thu, May 07, 2026 · 7:30 AM ET

    Watch Transcript

  • Pharming Group (Euronext:PHARM) Q4 2025 Earnings Call

    Thu, Mar 12, 2026 · 8:30 AM ET

    Watch Transcript

Latest news

Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November

Oct 27, 2026

Pharming Group announces third quarter 2026 revenues above market expectations

Oct 22, 2026

Pharming presents positive Phase II topline data for leniolisib in genetic PIDs with immune dysregulation at ESID 2026

Oct 14, 2026

Pharming announces CEO transition

Sep 29, 2026

Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS

Sep 25, 2026

Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026

Sep 22, 2026

FDA approves Pharming's Joenja(R) as first treatment for children with APDS in the U.S.

Sep 14, 2026

FDA approves Pharming’s Joenja® as first treatment for children with APDS in the U.S.

Sep 11, 2026

Pharming Group to participate in September investor conferences

Sep 9, 2026

Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older

Aug 13, 2026

All Pharming Group NV news

Decks

Pharming Group NV on 6ix

Sector
Health care
Industry
Biotechnology
News releases
35 in the last 12 months · 54 in all · newest Oct 27, 2026 · oldest 2025
Calls
13 calls with a replay · 13 with a transcript · latest Jul 30, 2026
Decks
50 decks · latest Oct 27, 2026

Where Pharming Group NV is listed

ListingExchangeCountryCurrency
Euronext:PHARM · Home listingEuronextNetherlandsEUR
NASDAQ:PHARNASDAQUnited StatesUSD
Aquis:PHARMAAquisUnited KingdomEUR
LSIN:0QCOLSINUnited KingdomEUR
gettex:PHGNgettexGermanyEUR
Aquis:PHARMAAquisUnited KingdomEUR
Tradegate:PHGNTradegateGermanyEUR
Xetra:PHGNXetraGermanyEUR
LS Exchange:A1H65ALS ExchangeGermanyEUR
OTC:PHGUF · This pageOTCUnited StatesUSD
BOATS:PHARBOATSUnited StatesUSD
Turquoise:PHARMATurquoiseUnited KingdomEUR
gettex:PHGgettexGermanyEUR
Lang & Schwarz:A1H65ALang & SchwarzGermanyEUR
Frankfurt:PHGNFrankfurtGermanyEUR
Hamburg:PHGNHamburgGermanyEUR
Stuttgart:PHGStuttgartGermanyEUR
BX Swiss:PHGNBX SwissSwitzerlandCHF
Dusseldorf:PHGNDusseldorfGermanyEUR
Frankfurt:PHGFrankfurtGermanyEUR
Lang & Schwarz:A2QLQYLang & SchwarzGermanyEUR
LS Exchange:A2QLQYLS ExchangeGermanyEUR
Munich:PHGNMunichGermanyEUR
Dusseldorf:PHGDusseldorfGermanyEUR
Munich:PHGMunichGermanyEUR
Stuttgart:PHGNStuttgartGermanyEUR
Hanover:PHGNHanoverGermanyEUR

Log in to ask 6ix AI your own questions about Pharming Group NV.